Gynae BT 2017
BENEFIT FROM CONCOMITANT RADIOCHEMOTHERAPY
AUTHOR
RANDOMISATION ARMS STAGE
LOCOREGIONAL RECURRENCE
3 YEAR OVERALL SURVIVAL
RT + Cisplatin + HE RT+ HE
Bulky IB
9% 21% RR 0.51 (95% CI) 24.9% 30.4% RR 0.79 (90% CI)
83% 74% (p=0.008) 67% 57% (p=0.018) 65% 65% 47% (p=0.004) 75% 63% (p=0.004) 81% 71% (p=0.007) 69% 66% (p=0.42)
Keys et al N Engl J Med. 1999
RT + Cis/5-FU RT + HU
IIB,III, IVA
Whitney et al J Clin Oncol. 1999
RT + Cisplatin RT + Cis/5-FU+HU RT + HU
IIB,III, IVA
Not reported
Rose et al N Engl J Med. 1999 Morris et al N Engl J Med. 1999
RT + Cis/5-FU RT (pelvis + paraaortal)
IB-IVA (~70% IB-IIB in each group) IA2,IB, IIA
19% 35% RR 0.47 (95% CI)
HE + RT + Cis/5-FU HE + RT
5.5% 17%
Peters et al J Clin Oncol. 2000
RT+Cisplatin RT
IB-IVA Not reported
Pearcey et al J Clin Oncol. 2002
Made with FlippingBook - Online catalogs